Many diseases can only be diagnosed properly by looking at sections of the tissue post-mortem or from invasive biopsies. Imaging of subtle textural aspects of tissue is not possible due to low resolution in magnetic resonance (MR) images. bioProtonics has developed a method to measure tissue texture using MR data without the need for rendered images. In many diagnostic workflows, the bioProtonics technique could replace biopsies. Such applications include neurodegenerative disease, liver disease, osteoporosis, cancer, lung disease, prostate disease.
Foot Drop is a mobility disorder prevalent in patients that is a common result of neurological injuries or diseases such as stroke cerebral palsy, MS or brain tumors. Foot drop is characterized by the inability to lift the toes toward the shin. It inhibits the rhythmic swing phase of the gait, increasing the probability of falls and manifests in abnormal gait patters that inhibit mobility and create imbalances and stress. Currently, there is not a rehabilitative solution that is cost effective and practical for every day independent use. Dr. Tyler Susko has developed a shoe that provides a low-friction out-sole during the swing phase of the gait, and a high-friction out-sole during the stance phase of the gait. The design can be used on any style shoe. Preliminary pilot studies with impaired adults have shown immediate gait improvement.
Soft robotics shows promise for creating robots which are better able to navigate narrow and variable environments. The vine robot is able to extend its length many thousands of percent its body length with an internal pressurized vessel, which can be manipulated to change the direction of the robot tip. In testing, the vine robot is able to navigate through small passages and can even autonomously navigate towards light source with the addition of a camera.
Cayuga Biotech aims to develop nanopolyP, a nanoparticle laminated with short chain polyphosphate, for the treatment of acute bleeding. Cayuga's team includes PhD scientists who developed nanopolyP, a regulatory advisor with 23 years of experience at the FDA, and business advisors who have overseen 4 successful biotech exits. Thus far, Cayuga has acquired grant funding to allow significant initial pharmacological and toxicological development. Cayuga aims to build a team, develop a business plan, and complete the few remaining non-clinical studies to file an IND.